ClinicalTrials.gg
RecruitingNCT07531199PFLOUpdated Oct 2, 2026

Efficacy and Safety of a Releasable Intraluminal Suture Technique to Reduce Hypotony Following Glaucoma Surgery Using the Preserflo Device

An interventional study of Classical surgery and Intraluminal suture in Glaucoma, sponsored by Hôpital Privé de la Baie. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Hôpital Privé de la Baie · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 2, 2026Now RecruitingFirst site in France+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Glaucoma with a site in France — 10 open to participants now, 11 under way, none of them phase 3. Glaucoma · France.

Planned enrollment
10th of 38
192 · median 105
Started
2026
with 2 others
No phase
29 of 54
7 open now
Primary completion
2028-12
later than 8 of 10 live
Registered
54th of 54
by date
Lead sponsor
4 of 54
Hôpital Privé de la Baie

Among the 54 studies in Glaucoma with a site in France, this one is the 10th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2026, is one of 29 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 54th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

10 of the 54 studies in Glaucoma with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Glaucoma with a site in France, or all of them as a file.
02

Study summary

Glaucoma is a common and irreversible disease of the optic nerve. It is the second leading cause of blindness worldwide. Glaucoma can be treated with medication, laser therapy, or surgery; the latter is often necessary. Traditional surgeries are invasive and carry a high rate of complications (hypotony, endophthalmitis, cataracts, etc.). Consequently, several types of micro-invasive surgeries (MIGS) and less invasive but effective surgeries, LIGS, have been developed to reduce surgical risks while maintaining effectiveness in lowering intraocular pressure (IOP). PRESERFLO is a drainage system less than 1 mm thick that regulates the outflow of aqueous humor from the eye. It is made of a soft, flexible biomaterial that conforms to the curvature of the eye. This biomaterial does not trigger a negative immune response. PRESERFLO is an example of a recently developed, powerful LIGS procedure (with preliminary results demonstrating efficacy and safety). PRESERFLO is already in use in France (marketing authorization and CE marking obtained) and is covered by social security.

This technique is highly effective in lowering IOP, but it may be associated with hypotony, although less frequently than with trabeculectomy. The use of a releasable suture placed inside the Preserflo to limit drainage and, consequently, reduce the risk of hypotony has been described with good results in preliminary studies. Nevertheless, it is necessary to evaluate the efficacy and safety of this technical modification in a randomized, prospective clinical trial to better understand whether this modification is beneficial for improving the treatment of patients with glaucoma.

03

Conditions studied

  • Glaucoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary open-angle glaucoma, pseudoexfoliative glaucoma or pigmentary glaucoma with an indication for glaucoma surgery (defined as uncontrolled intraocular pressure or worsening of visual fields, despite maximum tolerated medical therapy) and an open iridocorneal angle (trabeculum visible on gonioscopy, Shaffer classification grade 3-4)

    • Healthy, mobile conjunctiva (without scarring or adhesions).
    • The indication for glaucoma surgery is defined as uncontrolled IOP or worsening of visual fields despite maximum tolerated medical therapy, and with either a previous failure of trabeculectomy or a risk of failure.
    • Maximum tolerated medical therapy: 3 or more classes of ocular hypotensive treatment, or fewer if there is an allergy or intolerance to the treatment. Visual field defects must be more severe than -3 dB in mean deviation.

Exclusion criteria

Exclusion Criteria:

  • severe systemic pathologies
  • other ophtalmic pathologies (except cataract)
  • previous intraocular surgery (except cataract)
  • neovascular glaucoma or iris neovascularization
  • pachymetry \< 490µm or > 620µm
  • to PRESERFLO Microshunt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Active comparator
    classical surgery

    Procedure: Classical surgery

  • Experimental
    Intraluminal suture

    Procedure: Intraluminal suture

Interventions

  • ProcedureClassical surgery

    After peritomy, coagulation, and the application of 0.04% mitomycin C (as in a trabeculectomy or any filtration surgery), a scleral tunnel is created 3 mm from the limbus using a 1-mm scalpel designed for this purpose, followed by a 25G needle, which is inserted into the eye parallel to the iris. Next, the Preserflo is inserted into this tunnel, away from the cornea and the iris. The outflow of aqueous humor through the Preserflo is tested by injecting BSS into the anterior chamber. The peritomy is then closed (as in a trabeculectomy).

  • ProcedureIntraluminal suture

    A 9-0 Ethilon suture is inserted into the distal end of the Preserflo to partially occlude the outflow of aqueous humor through this drain, thereby reducing the risk of postoperative hypotony. The other end of this suture is attached to the cornea, forming a loop (which will allow it to be removed later). Next, the Preserflo and the suture are covered with the Tenon's capsule and the conjunctiva, as in the standard technique.

06

What researchers measure

Primary outcomes

  1. Postoperative hypotonia

    IOP ≤ 6 mmHg with vision loss, hypotensive maculopathy, or visible choroidal detachment, as determined during two consecutive visits. Intraocular pressure will be measured using Goldman applanation tonometry

    Time frame: 12 months after surgery

Secondary outcomes

  1. Complete surgical success

    It is defined as a reduction in intraocular pressure of at least 20%, without medication, and without a loss of more than 2 lines of visual acuity, major complications, or the need for further glaucoma surgery

    Time frame: 12 months after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.

Of 230 non-industry interventional studies with no phase under Glaucoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 27 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 12 and three quarters within 53.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Sep 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 15, 2026
StartActual
Sep 17, 2026was May 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Feb 28, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added — first site in France
Show site
  • Hôpital Privé de la Baie · Avranches, France
Oct 2, 2026
Start date
May 1, 2026→Sep 17, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • Hôpital Privé de la Baie · Avranches, France
    Start date May 1, 2026→Sep 17, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07531199
Lead sponsor
Hôpital Privé de la Baie
Responsible party
Sponsor
First posted
Apr 15, 2026
Start date
Sep 17, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Marion Mandon, PhD
Contact
mmandon@vivalto-sante.com
+33 6 78 27 76 72
Ana Miguel, MD
principal investigator · Hôpital Privé de la Baie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion